Figure 2.
Figure 2. Dose response analyses of pan PIM inhibitor (pPIMi), idelalisib (CAL-101) and PIM/PI3-kinase inhibitor (IBL-202) against primary CLL patient samples (n = 9).

Dose response analyses of pan PIM inhibitor (pPIMi), idelalisib (CAL-101) and PIM/PI3-kinase inhibitor (IBL-202) against primary CLL patient samples (n = 9).

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal